{"id":38086,"date":"2025-07-29T12:01:38","date_gmt":"2025-07-29T04:01:38","guid":{"rendered":"https:\/\/flcube.com\/?p=38086"},"modified":"2025-07-29T12:01:39","modified_gmt":"2025-07-29T04:01:39","slug":"astrazeneca-restructures-biopharm-business-to-strengthen-autoimmune-and-respiratory-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38086","title":{"rendered":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies"},"content":{"rendered":"\n

UK-based AstraZeneca’s (AZ, NASDAQ: AZN<\/a>) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.<\/p>\n\n\n\n

Respiratory Biologics and Autoimmune Business Unit<\/strong>
The Respiratory Biologics and Autoimmune Business Unit will focus on biologics and future autoimmune product pipelines. It will cover key product lines including Fasenra, Tezspire, Tozorakimab, and Saphnelo. This unit requires strong academic capabilities to drive the transition towards biologics. Sophie Zhang will join AstraZeneca China on July 29 as Assistant Vice President and Head of this new unit. She will also be part of the AstraZeneca China Management Team, reporting directly to Leon Lin, General Manager of AstraZeneca China.<\/p>\n\n\n\n

Respiratory Inhalation Business Unit<\/strong>
The Respiratory Inhalation Business Unit will continue to collaborate closely with omnichannel teams to align with national grassroots healthcare policies. It aims to expand into lower-tier markets and extend innovative therapies from core hospitals to communities. This unit will include the Breztri, Symbicort, and Bevespi product lines. William Tong, currently Assistant Vice President and Head of the COPD Business at AstraZeneca China, will lead this new unit as Assistant Vice President and Head of the Respiratory Inhalation Business Unit, reporting directly to Leon Lin.<\/p>\n\n\n\n

Leadership Promotions<\/strong>
Additionally, AstraZeneca has promoted Baiyang Li, the current Head of Retail Business, to Assistant Vice President and Head of Retail Business for AstraZeneca China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a…<\/p>\n","protected":false},"author":1,"featured_media":38087,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,871],"class_list":["post-38086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astrazeneca","tag-az","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38086\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies\" \/>\n<meta property=\"og:description\" content=\"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38086\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-29T04:01:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-29T04:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies\",\"datePublished\":\"2025-07-29T04:01:38+00:00\",\"dateModified\":\"2025-07-29T04:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086\"},\"wordCount\":255,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2904.webp\",\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38086#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38086\",\"name\":\"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2904.webp\",\"datePublished\":\"2025-07-29T04:01:38+00:00\",\"dateModified\":\"2025-07-29T04:01:39+00:00\",\"description\":\"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38086\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2904.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38086#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies - Insight, China's Pharmaceutical Industry","description":"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38086","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies","og_description":"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.","og_url":"https:\/\/flcube.com\/?p=38086","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-29T04:01:38+00:00","article_modified_time":"2025-07-29T04:01:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38086#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38086"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies","datePublished":"2025-07-29T04:01:38+00:00","dateModified":"2025-07-29T04:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38086"},"wordCount":255,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38086#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","keywords":["AstraZeneca","AZ","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38086#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38086","url":"https:\/\/flcube.com\/?p=38086","name":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38086#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38086#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","datePublished":"2025-07-29T04:01:38+00:00","dateModified":"2025-07-29T04:01:39+00:00","description":"UK-based AstraZeneca's (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a significant structural reorganization. The company announced the formation of two new business units: the Respiratory Biologics and Autoimmune Business Unit and the Respiratory Inhalation Business Unit.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38086#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38086"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38086#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","width":1080,"height":608,"caption":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38086#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38086"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38086\/revisions"}],"predecessor-version":[{"id":38088,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38086\/revisions\/38088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38087"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}